Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer
Shots:
- The first patient has been dosed in P-l/ll adaptive-design study assessing the safety- tolerability- pharmacokinetics- and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed
- The initiation of the study follows the identification of the RP2D in the ongoing study of LNS8801. The company anticipates opening several more phase 2 dose-expansion cohorts exploring LNS8801 activity as a monothx. and in combination with other compounds in 2021
- LNS8801 (PO) is a bioavailable small molecule that is a highly specific and potent agonist of the GPER and has demonstrated target engagement and clinical benefit in advanced cancer patients. P-l/ll study’s results are anticipated to be presented in a peer-reviewed setting in 2021
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com